(Q38125078)

29 August 2017

0 references

Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis (English)

1 reference

inflammatory bowel diseases

29 August 2017

main subject

0 references

ascending cholangitis

0 references

1 reference

1 reference

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

1 reference

Jonathan D Hansen

1

1 reference

29 August 2017

Sonal Kumar

2

1 reference

29 August 2017

Wai-Kit Lo

3

1 reference

29 August 2017

David M Poulsen

4

1 reference

29 August 2017

Umme-Aiman Halai

5

1 reference

29 August 2017

Kathy C Tater

6

1 reference

29 August 2017

publication date

30 July 2013

1 reference

Digestive Diseases and Sciences

29 August 2017

published in

1 reference

29 August 2017

volume

58

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

3079-3087

1 reference

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Cancer risk in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2772-0

Primary sclerosing cholangitis

21 January 2018

1 reference

12 December 2020

The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis

1 reference

12 December 2020

Primary sclerosing cholangitis

1 reference

12 December 2020

Sclerosing Cholangitis: Its Increasing Frequency of Recognition and Association with Inflammatory Bowel Disease

1 reference

12 December 2020

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.

1 reference

12 December 2020

10.1007/S10620-013-2772-0

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1028276587

0 references

1 reference